Clinical trials
Osteosarcoma in Children clinical trials
Below are recruiting osteosarcoma in children clinical trials, each written for real people, not researchers. We’re tracking 15 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07144254RecruitingPhase 1
Tegavivint and gemcitabine for relapsed osteosarcoma
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
Atlanta, GeorgiaAges 1–30 - NCT06650514RecruitingPhase 2
OMO-103 for advanced osteosarcoma
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
BarcelonaAges 12 years+ - NCT06235125RecruitingPhase 1
Using Cytalux during lung surgery in children and teens
This study tests whether a dye called Cytalux, injected before lung surgery, can help surgeons see and remove cancer spots in children and teens with certain cancers. It may help make sure all visible cancer is removed during the operation.
Chicago, IllinoisAges 6–17 - NCT06935864Recruiting
Study of KLF4 and KLF7 in bone tumors
This study looks at two proteins, KLF4 and KLF7, in bone tumor samples. It aims to understand their role in osteosarcoma and Ewing sarcoma, which may help develop better treatments.
CairoAges 1 month–39 years - NCT06156410RecruitingPhase 1
Cabozantinib and ifosfamide for relapsed sarcomas
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
San Francisco, CaliforniaAges 5–40 - NCT05235165RecruitingPhase 3
Surgery choice for lung spread of osteosarcoma
This Phase 3 trial compares two ways to remove lung metastases (open surgery vs keyhole surgery) in people with osteosarcoma. It aims to see which approach works better and is safer for patients with a limited number of lung spots that can be removed.
Birmingham, AlabamaAges Up to 50 years - NCT07428993RecruitingPhase 2
CAR T-Cell Therapy for High-Risk Osteosarcoma
This trial tests a new type of cell therapy called B7-H3 CAR T cells for children and young adults with high-risk osteosarcoma that hasn't spread or worsened after standard chemotherapy. The treatment uses your own immune cells that are modified to attack a protein (B7-H3) found on cancer cells.
Memphis, TennesseeAges Up to 21 years - NCT07514819Recruiting
Adaptive Proton Therapy Planning for Children With Cancer
This study tests a new way to plan proton radiation therapy (a precise type of cancer treatment) for children with solid tumors or Hodgkin's lymphoma. The goal is to improve how doctors adapt treatment during therapy to better target tumors while protecting healthy tissue.
Memphis, TennesseeAges Any age - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT07222735RecruitingPhase 1
CAR T cells and radiation for children with sarcoma
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
Memphis, TennesseeAges Up to 21 years - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Birmingham, AlabamaAges Any age - NCT04897321RecruitingPhase 1
CAR T therapy for children with B7-H3 solid tumors
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
Memphis, TennesseeAges Up to 21 years - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years
Hear when a new Osteosarcoma in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for osteosarcoma in children?
- Yes. Clin2 currently lists 15 recruiting osteosarcoma in children studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a osteosarcoma in children trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a osteosarcoma in children trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.